Camber Capital Management as of March 31, 2019
Portfolio Holdings for Camber Capital Management
Camber Capital Management holds 28 positions in its portfolio as reported in the March 2019 quarterly 13F filing
Company (Ticker) |
Portfolio Weight |
Valued At |
Change in Shares |
Share Count |
Share Price |
|---|---|---|---|---|---|
| Spdr S&p 500 Etf (SPY) | 14.1 | $283M | 1.0M | 282.48 | |
| Allergan | 9.5 | $190M | 1.3M | 146.41 | |
| Mylan Nv | 8.1 | $163M | 5.8M | 28.34 | |
| Perrigo Company (PRGO) | 5.0 | $101M | 2.1M | 48.16 | |
| Global Blood Therapeutics In | 4.8 | $95M | 1.8M | 52.93 | |
| Biogen Idec (BIIB) | 4.7 | $95M | 400k | 236.38 | |
| Universal Health Services (UHS) | 4.3 | $87M | 650k | 133.77 | |
| DaVita (DVA) | 4.1 | $81M | 1.5M | 54.29 | |
| Alexion Pharmaceuticals | 4.0 | $81M | 600k | 135.18 | |
| Atara Biotherapeutics | 4.0 | $80M | 2.0M | 39.75 | |
| Brookdale Senior Living (BKD) | 3.6 | $72M | 11M | 6.58 | |
| Medicines Company | 3.4 | $69M | 2.5M | 27.95 | |
| Nektar Therapeutics (NKTR) | 3.4 | $67M | 2.0M | 33.60 | |
| Sarepta Therapeutics (SRPT) | 3.0 | $60M | 500k | 119.19 | |
| Momenta Pharmaceuticals | 2.9 | $58M | 4.0M | 14.53 | |
| Teva Pharmaceutical Industries (TEVA) | 2.7 | $55M | 3.5M | 15.68 | |
| Bristol Myers Squibb (BMY) | 2.6 | $53M | 1.1M | 47.71 | |
| Ascendis Pharma A S (ASND) | 2.5 | $51M | 430k | 117.70 | |
| Tenet Healthcare Corporation (THC) | 2.5 | $51M | 1.8M | 28.84 | |
| NuVasive | 2.1 | $43M | 750k | 56.79 | |
| Synthorx | 1.9 | $38M | 1.9M | 20.37 | |
| Clovis Oncology | 1.9 | $37M | 1.5M | 24.82 | |
| Zymeworks | 1.8 | $35M | 2.2M | 16.18 | |
| AMAG Pharmaceuticals | 1.7 | $34M | 2.7M | 12.88 | |
| Eagle Pharmaceuticals (EGRX) | 0.7 | $15M | 292k | 50.49 | |
| Sutro Biopharma (STRO) | 0.3 | $6.8M | 600k | 11.39 | |
| Endologix | 0.3 | $6.1M | 930k | 6.61 | |
| Surgery Partners (SGRY) | 0.1 | $1.8M | 160k | 11.28 |
